Morepen Laboratories Ltd's Q3FY25 Quarter Results
- 07 Feb 2025
Result Summary
- Morepen Laboratories Ltd reported a 3.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 2.1%.
- Its expenses for the quarter were up by 6.6% QoQ and 4.5% YoY.
- The net profit decreased 23.4% QoQ and decreased 16.6% YoY.
- The earnings per share (EPS) of Morepen Laboratories Ltd stood at 0.5 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 458.12 | 442.71 | 448.62 | 3.5% | 2.1% |
Total Expenses | 422.91 | 396.70 | 404.61 | 6.6% | 4.5% |
Profit Before Tax | 35.21 | 46.02 | 44.02 | -23.5% | -20.0% |
Tax | 8.52 | 11.17 | 12.03 | -23.7% | -29.2% |
Profit After Tax | 26.69 | 34.85 | 31.99 | -23.4% | -16.6% |
Earnings Per Share | 0.50 | 0.70 | 0.60 | -28.6% | -16.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Morepen Laboratories Ltd is a well-established pharmaceutical company operating primarily in the healthcare and wellness sector. The company is known for its diverse range of products, including pharmaceuticals, diagnostics, and over-the-counter (OTC) products. Morepen Laboratories has been a significant player in the pharmaceutical industry, focusing on both domestic and international markets. The company has made notable progress in expanding its product portfolio and increasing its market reach. While specific recent developments are not provided in the data, the company continues to maintain a strong presence in its industry.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Morepen Laboratories Ltd reported a total income of ₹458.12 crores. This figure represents a 3.5% increase quarter-over-quarter (QoQ) from the previous quarter (Q2FY25), where the total income was ₹442.71 crores. On a year-over-year (YoY) basis, there was a 2.1% growth compared to the same quarter last year (Q3FY24), which recorded a total income of ₹448.62 crores. The steady increase in total income highlights the company's ability to sustain revenue growth over the observed periods.
Profitability
The company's profitability in Q3FY25 showed a decline compared to both the previous quarter and the same period last year. Profit Before Tax (PBT) for Q3FY25 was ₹35.21 crores, representing a decrease of 23.5% QoQ and 20.0% YoY. The tax expense for Q3FY25 amounted to ₹8.52 crores, which was down by 23.7% QoQ and 29.2% YoY. Consequently, Profit After Tax (PAT) for the quarter stood at ₹26.69 crores, reflecting a 23.4% reduction QoQ and a 16.6% decrease YoY. Earnings Per Share (EPS) similarly fell to ₹0.50, declining by 28.6% QoQ and 16.7% YoY. These figures indicate a noticeable reduction in profitability metrics during the quarter.
Operating Metrics
The total expenses for Morepen Laboratories Ltd in Q3FY25 were reported at ₹422.91 crores, marking a 6.6% increase QoQ from ₹396.70 crores in Q2FY25 and a 4.5% rise YoY from ₹404.61 crores in Q3FY24. This upward trend in expenses, in conjunction with the changes in revenue, reflects on the company's operational scale and cost management over the period. Although the expenses have grown, the total income increase has not proportionately matched the expense rise, impacting the profitability metrics. The data does not provide specific details on financial ratios like P/E ratio, debt-to-equity ratio, or current ratio for further analysis.
